Nuvalent presses ahead in ALK
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
EnGene squares up to J&J
New detalimogene bladder cancer data send the minnow’s stock up 47%.
Immatics’ PRAME T-cell engager improves
The response rate jumps to 30% with higher doses of IMA402.
Crispr cans a next-gen project
The CD70-targeting CTX131 heads for the scrapheap.
Cogent sets the KIT bar for GSK
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
SITC 2025 – fresh hope for Summit's Harmoni
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
